Tags

Type your tag names separated by a space and hit enter

MP-AzeFlu provides rapid and effective allergic rhinitis control: results of a non-interventional study in Romania.
Rhinology. 2018 Mar 01; 56(1):33-41.R

Abstract

BACKGROUND

Allergic Rhinitis and its Impact on Asthma (ARIA) and the European Union (EU) recommend a shift to guide allergic rhinitis (AR) treatment decisions from symptom severity to disease control, using a simple visual analogue scale (VAS). Using this VAS we assessed, in a real-life study in Romania, the effectiveness of MP-AzeFlu nasal spray.

METHODOLOGY

In this multi-centre, prospective, non-interventional study, 253 patients (over 11 years old) with moderate-to-severe AR were prescribed MP-AzeFlu and assessed their symptoms on a VAS (0 (not at all bothersome) to 100 mm (very bothersome)) on Days 0, 1, 3, 7 and 14. The proportion of patients who achieved a defined VAS score cut-off for well-controlled (38 mm) AR were also calculated. Patients perception of disease control was assessed on Day 3.

RESULTS

MP-AzeFlu use was associated with a mean (standard deviation) VAS score reduction from 78.4 (15.1) mm at baseline to 14.7 (15.1) mm on the last day. Effectiveness was consistent irrespective of disease severity, phenotype or patient age. 83.4% of patients achieved the smaller than 39 mm well-controlled VAS score cut-off by last day and 95.2% considered their symptoms to be well- or partly controlled at Day 3.

CONCLUSIONS

MP-AzeFlu provided rapid, effective and sustained AR symptom control in a real-life setting in Romania, irrespective of severity, phenotype or patient age, aligning with ARIA and EU recommendations and supporting the position of MP-AzeFlu as the drug of choice for the treatment of moderate-to-severe AR.

Authors+Show Affiliations

Transylvania University of Brasov, Faculty of Medicine, Department of Allergy and Clinical Immunology, Brasov, Romania.University of Medicine and Pharmacy Victor Babes, ENT Department, Timisoara, Romania.Carol Davila University of Medicine and Pharmacy, Family Medicine Department, Bucharest, Romania and Colentina Clinical Hospital, Internal Medicine Department, Bucharest, Romania.Nicolae Malaxa Hospital, Allergology Outpatient Unit, Bucharest, Romania.University of Medicine and Pharmacy Victor Babes, ENT Department, Timisoara, Romania.Carol Davila University of Medicine and Pharmacy, Family Medicine Department, Bucharest, Romania and Santa Maria Hospital, University of Medicine and Pharmacy, Department of ORL.

Pub Type(s)

Journal Article
Multicenter Study

Language

eng

PubMed ID

28942457

Citation

Agache, I, et al. "MP-AzeFlu Provides Rapid and Effective Allergic Rhinitis Control: Results of a Non-interventional Study in Romania." Rhinology, vol. 56, no. 1, 2018, pp. 33-41.
Agache I, Doros IC, Leru PM, et al. MP-AzeFlu provides rapid and effective allergic rhinitis control: results of a non-interventional study in Romania. Rhinology. 2018;56(1):33-41.
Agache, I., Doros, I. C., Leru, P. M., Bucur, I., Poenaru, M., & Sarafoleanu, C. (2018). MP-AzeFlu provides rapid and effective allergic rhinitis control: results of a non-interventional study in Romania. Rhinology, 56(1), 33-41. https://doi.org/10.4193/Rhin16.278
Agache I, et al. MP-AzeFlu Provides Rapid and Effective Allergic Rhinitis Control: Results of a Non-interventional Study in Romania. Rhinology. 2018 Mar 1;56(1):33-41. PubMed PMID: 28942457.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - MP-AzeFlu provides rapid and effective allergic rhinitis control: results of a non-interventional study in Romania. AU - Agache,I, AU - Doros,I C, AU - Leru,P M, AU - Bucur,I, AU - Poenaru,M, AU - Sarafoleanu,C, PY - 2017/9/25/pubmed PY - 2018/4/25/medline PY - 2017/9/25/entrez SP - 33 EP - 41 JF - Rhinology JO - Rhinology VL - 56 IS - 1 N2 - BACKGROUND: Allergic Rhinitis and its Impact on Asthma (ARIA) and the European Union (EU) recommend a shift to guide allergic rhinitis (AR) treatment decisions from symptom severity to disease control, using a simple visual analogue scale (VAS). Using this VAS we assessed, in a real-life study in Romania, the effectiveness of MP-AzeFlu nasal spray. METHODOLOGY: In this multi-centre, prospective, non-interventional study, 253 patients (over 11 years old) with moderate-to-severe AR were prescribed MP-AzeFlu and assessed their symptoms on a VAS (0 (not at all bothersome) to 100 mm (very bothersome)) on Days 0, 1, 3, 7 and 14. The proportion of patients who achieved a defined VAS score cut-off for well-controlled (38 mm) AR were also calculated. Patients perception of disease control was assessed on Day 3. RESULTS: MP-AzeFlu use was associated with a mean (standard deviation) VAS score reduction from 78.4 (15.1) mm at baseline to 14.7 (15.1) mm on the last day. Effectiveness was consistent irrespective of disease severity, phenotype or patient age. 83.4% of patients achieved the smaller than 39 mm well-controlled VAS score cut-off by last day and 95.2% considered their symptoms to be well- or partly controlled at Day 3. CONCLUSIONS: MP-AzeFlu provided rapid, effective and sustained AR symptom control in a real-life setting in Romania, irrespective of severity, phenotype or patient age, aligning with ARIA and EU recommendations and supporting the position of MP-AzeFlu as the drug of choice for the treatment of moderate-to-severe AR. SN - 0300-0729 UR - https://www.unboundmedicine.com/medline/citation/28942457/MP_AzeFlu_provides_rapid_and_effective_allergic_rhinitis_control:_results_of_a_non_interventional_study_in_Romania_ L2 - https://www.rhinologyjournal.com/Abstract.php?id=1646 DB - PRIME DP - Unbound Medicine ER -